Retrospective Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Feb 26, 2024; 12(6): 1104-1110
Published online Feb 26, 2024. doi: 10.12998/wjcc.v12.i6.1104
Table 1 Coronavirus disease 2019 kidney transplant recipients characteristics (n = 321)
Characteristics
Number (%) of patients
Range
Sex
Male/female183/138 (57/43)
Age (yr) [Median (IQR)]
Primary kidney disease
55 (44-64)22-81
    Glomerulonephritis9 + 8 (30.6)
    Diabetic nephropathy12 (3.8)
    ADPKD48 (15)
    Pyelonephritis26 (8.1)
    Nephroangiosclerosis26 (8.1)
    Other110 (34.4)
Time from transplantation (months) [Median (IQR)]94.5 (52-135.8)1-368
Height (cm) [Median (IQR)]171 (163-180)124-199
Body weight (kg) [Median (IQR)]79 (67-92)42-150
BMI [Median (IQR)]26.5 (23.9-29.2)17.36-45.79
Nutritional status
    Underweight (BMI < 18.5)4 (1.3)
    Normal weight105 (32.8)
    Pre-obesity (25-29.9)144 (45)
    Obese (≥ 30)67 (20.9)
Previous thrombosis30 (9.4)
Previous myocardial infarction or stroke32 (10)
Previous CMV infection36 (11.3)
Previous BK infection68 (21.3)
Previous EBV infection28 (8.8)
Allograft rejection46 (14.4)
Creatinine value [Median (IQR)]129 (98-165.8)45-430
CKD EPI [Median (IQR)]49 (35-64)0.23-133
Biuret [Median (IQR)]0.2 (0.1-0.5)0-79
Vaccinated against COVID-19246 (76.9)
    Before COVID-19 infection149 (46.6)
    After COVID-19 infection97 (30.3)
Number of vaccine doses [Median (IQR)]2 (2-3)1-4
Number of vaccine doses (n = 246)
    One21 (8.5)
    Two138 (56.1)
    Three83 (33.7)
    Four4 (1.6)
COVID-19 initial symptoms
    Febrility245 (76.6)
    Diarrhea39 (12.2)
    Respiratory230 (71.9)
Asymptomatic 21 (6.6)
COVID-19 initial complications
Hospitalisation125 (39.1)
Pneumonia141 (44.1)
Mechanical ventilation4 (1.3)
Other66 (20.6)
Initial immunosuppression
Tacrolimus222 (69.4)
Cyclosporin A70 (21.9)
Mycophenolate280 (87.5)
Azathioprine12 (3.8)
Everolimus48 (15)
Prednisolone (dose) [Median (IQR)]5 (5-5)0-30
Acute COVID-19 treatment
Cessation of MMF/Aza133 (41.6)
Decreasing MMF/Aza102 (31.9)
Cessation of Tac/CyA1 (0.3)
Decreasing Tac/CyA29 (9.1)
Hyperimmune anti-CMV globulin30 (9.4)
Intravenous immunoglobulin13 (4.4)